 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Otsuka Pharmaceutical Co., Ltd. |
| Street 1: | 3-2-27 Otedori, Chuo-ku |
| Street 2: | |
| City: | Osaka |
| Province: | |
| Post Code: | 540-0021 |
| Country: | Japan |
| Phone: | +41 22 560 79 60 |
| Email: | info@otsuka-sa.ch |
| Web Site: | http://www.otsuka.com |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Private sector |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Is your organization legally registered in your country: | Yes |
| Organization Reach: | International |
| Organization Description: | |
| Founded in 1964, Otsuka Pharmaceutical Co., Ltd. (Otsuka) is a global healthcare company with the corporate philosophy ‘Otsuka-people creating new products for better health worldwide.’ Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to the high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural environment. |
|
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 51 - 99 |
| Number of part-time staff who are directly involved with TB: | 0 |
| Number of volunteers who are directly involved with TB: | 0 |
| What is your organization's annual budget (USD) dedicated to TB? | >$10 MIL |
| How did you hear about the Stop TB Partnership: | Stop TB communications |
| Why do you wish join the Stop TB Partnership: | Information on developments within the TB world |
| Are you a member of a Stop TB national partnership: | Japan |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| Otsuka conducts clinical trials in Japan, among other countries, for the development of a novel compound for the treatment of multidrug-resistant tuberculosis (MDR-TB). | |
Geographical Reach | |
| Which country is your headquarters located in: | Japan |
| Which WHO region is the main focus of your work: | Western Pacific |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
China Czech Republic Egypt Estonia France Germany Indonesia Italy Japan Latvia Lithuania Pakistan Peru Philippines Republic of Korea Republic of Moldova South Africa Spain Sweden Switzerland United Kingdom of Great Britain and Northern Ireland United States of America Viet Nam |
Specializations | |
|
Advocacy, communication and social mobilization Provision of drugs, diagnostics and commodities Research and Development |
Specializations in Countries | |
| Advocacy, communication and social mobilization | Republic of Moldova |
| Advocacy, communication and social mobilization | Switzerland |
| Research and Development | China |
| Research and Development | Egypt |
| Research and Development | Estonia |
| Research and Development | Germany |
| Research and Development | Japan |
| Research and Development | Latvia |
| Research and Development | Lithuania |
| Research and Development | Peru |
| Research and Development | Philippines |
| Research and Development | Republic of Korea |
| Research and Development | South Africa |
| Research and Development | United States of America |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
Drug-Resistant TB: As a recognized leader in TB R&D, Otsuka is committed to helping eliminate this devastating disease. For more than 30 years Otsuka has made TB research a priority, and is currently working on the development of a novel compound for multidrug-resistant TB (MDR-TB). More information may be found at: http://clinicaltrials.gov/ct2/show/NCT01424670 TB-HIV: As part of our Phase III clinical trial, MDR-TB study subjects with co-existing HIV infection who are currently taking antiretrovirals (ARVs) will be randomized to receive six months of delamanid plus an optimized background regimen (OBR) according to WHO treatment guidelines or placebo plus OBR. Laboratory Strengthening: Otsuka engaged in capacity building and infrastructure development in many clinical sites in the nine countries where the Phase II trial of delamanid took place. This unique investment included infrared lighting, larger hospital rooms with better ventilation, laboratory equipment and extensive training in some locations. All sites in which we operate followed the most stringent Good Clinical Practice (GCP) standards. Our work in this area underscores the company’s strong commitment to MDR-TB treatment beyond the testing of our new compound. New TB Drugs: Continuing its commitment to TB R&D, Otsuka recently initiated an international Phase III clinical study for MDR-TB. More information may be found at http://clinicaltrials.gov/ct2/show/NCT01424670 |
|
Declaration | |
| Declaration of interests: I am a full-time employee of Otsuka Pharmaceutical Co., Ltd. | |
| Application date: | February 4, 2010 |
| Last updated: | October 22, 2012 |